JSJenny I. Shen

Jenny I. Shen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jenny I. Shen has a total of 302 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Does Remote Monitoring Improve Time on Peritoneal Dialysis?: Commentary

    by Jenny I. Shen, Tiane Dai

  • Validating the standardised outcomes in nephrology-life participation (SONG-LP) measure in people receiving peritoneal dialysis: Rationale and process

    by Cameron Thomas Burnett, Allison Jaure, Anastasia Hughes, Angela Ju, Martin Howell, Karine Manera, Melissa Cheetham, David Wayne Johnson, Martin Wilkie, Fiona Loud, et al.

    Life participation has been identified as a critically important core outcome to be reported in all trials in people receiving peritoneal dialysis (PD). Life participation is defined as the ability to participate in meaningful activities such as work (e.g. employment, housework, study), family, social (e.g. time with friends) and leisure (travel, hobbies, exercise) activities. However, life participation is rarely and inconsistently reported in trials in PD. The standardised outcomes in nephrology-life participation (SONG-LP) instrument was validated in adult kidney transplant recipients and demonstrated internal consistency and test–retest reliability. In this article, we outline the rationale and process for validating the SONG-LP instrument in people receiving PD.


  • International Society for Peritoneal Dialysis Journal Club

    by Osama El Shamy, Ankur D. Shah, Megha Salani, Matthew B. Rivara, Isaac Teitelbaum, Rob Quinn, Jenny I. Shen, Thomas Golper

  • Experiences and perspectives of patients and their caregivers on gastrointestinal symptoms in peritoneal dialysis: Workshop report

    by Ashik Hayat, David W Johnson, Karine Manera, Andrea K Viecelli, Martin Wilkie, Jenny Shen, Angela Yee-Moon Wang, Htay Htay, Allison Jaure, Yeoungjee Cho, et al.

    Introduction: Gastrointestinal (GI) symptoms are common and can be debilitating for patients receiving peritoneal dialysis (PD). However, they are rarely reported and there is no widely accepted or validated tool for measuring GI health in these patients to facilitate shared decision making. Methods: An online consensus workshop was conducted to describe the experiences and perspectives about the impacts of GI symptoms in patients receiving PD and their caregivers and suggestions for measuring GI symptoms in clinical practice and research. A diverse range of patients currently receiving PD or who received PD within the past 5 years and their caregivers from different regions were recruited. After the initial presentation, small-group facilitated discussions were conducted similarly to focus groups, followed by a large-group summarisation of the workshop findings. Transcripts were thematically analysed using an inductive approach informed by grounded theory. Summary of the workshop: Thirty-five participants attended the online workshop, including 32 patients and 3 caregivers from 7 countries. Four themes were identified: restricting the ability to live freely (inability to predict and prepare, s uffering from severe and disruptive symptoms) , persistent anguish and struggle (living in fear, isolated by burden) , uncertainty about healthcare management (inadequate education and information, lack of individualised care, experimenting to find solution s), measuring GI health in a relevant and robust manner ( enabling comprehensive symptom monitoring , individualising frequency of symptom recording , r ecommending user-friendly and innovative tools). Conclusion: This study demonstrated a high burden of GI symptoms in patients receiving PD. These symptoms were unpredictable in their onset, threatening patients’ wellbeing and quality of life. A feasible measure of GI symptoms needs to be developed and implemented to inform treatment decisions and aid in consistent reporting in PD trials.


  • The Association of Antiemetics Use With Incident Chronic Kidney Disease

    by Diana S. Kalantar, Rina Takahashi, Jenny I. Shen, Diana Tran, Adnan Ismail, Erika Lopez Pena, Mayara Abichequer-Beer, Fridtjof Thomas, Jun Ling Lu, Keiichi Sumida, et al.


  • The Association of Fibrate Use with Kidney Outcomes and Mortality

    by Rina Takahashi, Jenny Shen, Diana Tran, Ibrahim Elali, Tiane Dai, Anuja Shah, Ramnath Dukkipati, Adnan Ismail, Keiichi Sumida, Fridtjof Thomas, et al.

    Key Points: In this large national cohort of United States veterans followed over 14 years, fibrate was associated with a higher risk of incident CKD. Fibrate use was also associated with a lower risk of ESKD and all-cause mortality. Considering the potential long-term benefits, clinicians should not necessarily avoid fibrate use, with careful monitoring of kidney function. Background: Fibrate use can result in an acute increase in serum creatinine, making assessing kidney outcomes associated with fibrates difficult in studies with short follow-up times. In addition, there is limited research on certain kidney outcomes and mixed results of past studies. The aim of this study was to examine the association of fibrate use with incident CKD, ESKD, and mortality in a large national cohort of United States (US) Veterans. Methods: A retrospective cohort study was conducted to examine the association of de novo prescription of fibrate medications with incident CKD, ESKD, and mortality over up to 14 years of follow-up. Patients (N=688,382) were selected from the national Department of Veterans Affairs (VA) research database. Associations were examined in Cox proportional hazards model and Fine-Gray model adjusted for demographics, major comorbidities, laboratory measurements including baseline eGFR, albuminuria, and medications. Results: We identified 58,773 incident new fibrate users. The overall mean (SD) age was 59 (13) years, with 7% female, 18% Black, and 7% Hispanic. Fibrate users were more likely to be male, White, current smokers, and had higher frequencies of comorbidities. In the fully adjusted model, fibrate use (versus nonuse) was associated with a lower risk of death (hazard ratio, 0.91; 95% confidential interval, 0.89 to 0.93) and ESKD (0.80, 0.71 to 0.92) but with a higher risk of incident CKD (1.21, 1.19 to 1.24). Conclusions: In this large national cohort of US Veterans with long follow-up time, fibrate use was associated with a higher risk of incident CKD but a lower risk of ESKD and mortality. Further studies are needed to corroborate the potential benefits of fibrate on kidney function and survival.


  • Open Access

    Uptake of Peritoneal Dialysis by Minoritized Patients

    by Ivelina Arnaoudova, Clara Wilson, Katherine Rizzolo, Jenny Shen, Nahian Ehtesham, Jennifer Wilson, Ladan Golestaneh

    Key Points: In this study of minoritized patients referred to modality education before dialysis, a high proportion selected, but fewer initiated dialysis with, peritoneal dialysis (PD). Those who initiated with PD were younger, healthier, and more responsive to education staff than those who started with hemodialysis. Patients identified lack of emotional support and information about overcoming structural barriers to PD as shortfalls in the education program. Background: In a cohort of patients with late-stage kidney disease who completed dialysis modality education and who self-identified as racial ethnic minorities, we studied characteristics of those choosing peritoneal dialysis (PD) and perception of usefulness of the education session in modality selection. Methods: In this study of individuals with kidney failure cared for by nephrologists at Montefiore Medical Center, Bronx, New York, who were referred for modality education, we (1) tested the association of patient characteristics with modality selection in 113 patients from 2021 to 2023 and (2) examined patient perception of the quality of modality education from 13 semistructured interviews. We compared sociodemographic, clinical attributes, and patient responsiveness to attempts made by staff among those who selected and initiated PD with those who (1) did not select PD or (2) initiated on hemodialysis urgently. We performed qualitative analysis of interviews to reach consensus on theoretical domain framework concepts and how they fit events in the kidney failure trajectory. Results: Compared with individuals who required urgent hemodialysis, those who selected and were initiated on PD were younger (54 versus 66 years), had fewer comorbidities, and did not require as many attempts to schedule modality education. Qualitative analysis of interviews showed that experience with staff and quality of information conveyed during education was generally positive, but the following gaps were identified: lack of support for the emotional trauma of kidney failure diagnosis, inability to address structural barriers to PD specific to the patient population, and the lack of a deliberate program to lessen anxiety about the responsibility of PD. Conclusions: Incorporation of tailored content that addresses clinical comorbidity, structural barriers to care, and emotional trauma constitute aspects of modality education that can be improved to increase PD uptake among minoritized patients.


  • Disparities in Care

    by Jenny I. Shen, Jeffrey Perl

  • Open Access

    Establishing a peritoneal dialysis technique survival core outcome measure: A standardised outcomes in nephrology-peritoneal dialysis consensus workshop report

    by Emma H Elphick, Karine E Manera, Andrea K Viecelli, Jonathan C Craig, Yeoungjee Cho, Angela Ju, Jenny I Shen, Martin Wilkie, Samaya Anumudu, Neil Boudville, et al.

    Background: Technique survival, also reported with negative connotations as technique failure or transfer from peritoneal dialysis to haemodialysis, has been identified by patients, caregivers and health professionals as a critically important outcome to be reported in all trials. However, there is wide variation in how peritoneal dialysis technique survival is defined, measured and reported, leading to difficulty in comparing or consolidating results. Methods: We conducted an online international consensus workshop to establish a core outcome measure of technique survival. Discussions were analysed thematically. Results: Fifty-five participants including 14 patients and caregivers from 13 countries took part in facilitated breakout discussions using video-conferencing. The following themes were identified: capturing important aspects of the outcome (requiring a core event to define the outcome, distinguishing temporary from permanent events, recognising heterogeneous experiences of transfers), adopting appropriate neutral nomenclature (conveying with clarity, avoiding negative connotations), and ensuring feasibility and applicability (capturing data relevant to clinical and research settings, ease of adoption). The suggested definitions for the core outcome measure were ‘the event of a transfer to haemodialysis’, or ‘discontinuation of peritoneal dialysis’. Applying the principles described within the workshop, defining the outcome measure as a ‘transfer to haemodialysis’ was preferable. Conclusions: It is proposed that the core outcome of technique survival is redefined as ‘transfer to haemodialysis’ and that its components are standardised using simple, neutral terminology Components considered important by stakeholders included recording the reasons for transfer from peritoneal dialysis, and focussing on permanent events whilst ensuring the outcome remains easy to implement.


  • Prevalence and Outcomes of Chronic Kidney Disease-Associated Pruritus

    by Karthik K. Tennankore, Keith McCullough, Brian Bieber, Yeoungjee Cho, David W. Johnson, Talerngsak Kanjanabuch, Hideki Kawanishi, Yong-Lim Kim, Mark Lambie, Claudio Rigatto, et al.

    Key Points: CKD-associated pruritus is highly prevalent among peritoneal dialysis patients. Pruritus is associated with reduced health-related quality of life, and the composite of mortality and transfer to hemodialysis for peritoneal dialysis patients. Efforts to better identify and manage pruritus in this population are needed. Background: Pruritus is common in hemodialysis patients. Less is known about the prevalence and outcomes of pruritus among patients receiving peritoneal dialysis (PD). Herein, we describe the prevalence of pruritus and its associations with patient-reported outcomes (PROs) and mortality/transfer to hemodialysis. Methods: We analyzed a multicenter, international cohort of PD patients enrolled in the PD Outcomes and Practice Patterns Study from 2014 to 2022. Pruritus was assessed at entry into the PD Outcomes and Practice Patterns Study with a single-question Likert Scale capturing the extent to which patients were bothered by itch ranging from 1: not at all to 5: extremely . The kidney disease quality of life-36 and the Center for Epidemiological Studies Depression Scale assessed various PROs. Moderate-to-extreme pruritus was defined as a Likert scale score ≥3. The associations of pruritus with PROs were assessed using linear/logistic regression where appropriate. Death or hemodialysis transfer was assessed using multivariable Cox regression models. Results: Overall, 5535 patients from eight countries were included; 43% had moderate-to-extreme pruritus which was the highest in Thailand (50%) and the lowest in the United States (33%). The adjusted odds ratios of moderate-to-extreme pruritus were higher for diabetes, low albumin, and elevated phosphorus but lower for residual urine volume (adjusted odds ratio, 0.98 per 200 ml increase in 24-hour urine volume; 95% confidence interval, 0.96 to 1.00; P = 0.05). Patients with extreme pruritus had the lowest mental and physical health component scores and a higher burden of other PROs including restless legs and disturbed sleep. Overall, 921 patients died and 1150 were transferred to hemodialysis. Patients with moderate-to-extreme pruritus were at higher adjusted risk for death or hemodialysis transfer (adjusted hazard ratio, 1.12; 95% confidence interval, 1.02 to 1.23; P = 0.02) with similar point estimates for each subcomponent of the composite outcome. Conclusions: Pruritus is highly prevalent in PD and associated with poor health outcomes. Efforts to better identify and manage pruritus should be considered in this population.